SCHEMBL379503

SCHEMBL379503

Brc1csc2ccnc(NCc3ccccn3)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 2/20 0.50
NOD1 Q9Y239 2/20 0.50
MAPK1 P28482 1/20 0.50
ALDH1A1 P00352 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
POLB P06746 1/20 0.47
PKM P14618 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
EGFR P00533 1/20 0.46
MAOA P21397 2/20 0.45
MAOB P27338 2/20 0.45
MAPT P10636 3/20 0.45
RAB9A P51151 3/20 0.45
NPC1 O15118 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
LMNA P02545 2/20 0.43
GFER P55789 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379904 0.83 UTS2R (0.49) MAPK1ALDH1A1SMN1; SMN2EGFRRAB9A
SCHEMBL379387 0.83 TNF (0.69) TNFNOD1MAPK1ALDH1A1SMN1; SMN2
SCHEMBL2368690 0.80 MAPK1 (0.72) TNFNOD1MAPK1ALDH1A1SMN1; SMN2
SCHEMBL379852 0.78 UTS2R (0.54) MAPK1ALDH1A1SMN1; SMN2PKMEGFR
SCHEMBL379470 0.78 IGF1R (0.42) ALDH1A1SMN1; SMN2L3MBTL1MAOAMAOB
SCHEMBL379685 0.77 SMN1; SMN2 (0.47) MAPK1ALDH1A1SMN1; SMN2POLBL3MBTL1
SCHEMBL380611 0.73 HPGD (0.43) L3MBTL1CYP1A2CYP2C19LMNAGBA1
SCHEMBL31129045 0.69 CYP1A2 (0.46) MAPK1ALDH1A1PKMMAPTRAB9A
SCHEMBL379865 0.68 ESR1 (0.55) TNFNOD1MAPK1ALDH1A1CYP1A2
SCHEMBL10509411 0.67 MAOA (0.58) ALDH1A1SMN1; SMN2EGFRMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 TNF 953/4885NOD1 141/4885MAPK1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.